Cleaved-NOTCH2 (V1697) Antibody

What is Cleaved-NOTCH2 (V1697) Antibody and what epitope does it specifically recognize?

The Cleaved-NOTCH2 (V1697) Antibody is a rabbit polyclonal antibody that specifically recognizes a neoepitope in the Notch Intracellular Domain 2 (NICD2) created by γ-secretase cleavage of NOTCH2 adjacent to valine 1697. This antibody detects endogenous levels of activated NOTCH2 protein fragments resulting from proteolytic processing . The antibody is generated against a synthesized peptide derived from human NOTCH2 at amino acid range 1678-1727 . This specificity allows researchers to distinguish between the inactive full-length NOTCH2 receptor and its cleaved, activated form that participates in downstream signaling events.

What applications is the Cleaved-NOTCH2 (V1697) Antibody validated for?

The antibody has been validated for the following applications:

• Western Blot (WB): Recommended dilution 1:500-1:2000

• ELISA: Recommended dilution 1:10000

Other applications may require additional optimization by the researcher .

What species reactivity has been confirmed for this antibody?

The Cleaved-NOTCH2 (V1697) Antibody has confirmed reactivity against:

• Human

• Mouse

• Rat

This cross-species reactivity makes it valuable for comparative studies across different model organisms .

What is the recommended protocol for using this antibody in Western Blot applications?

For optimal Western Blot results with Cleaved-NOTCH2 (V1697) Antibody:

• Prepare protein lysates from cells of interest (studies have used Jurkat cells treated with etoposide 25μM for 24h as positive controls)

• Separate proteins using SDS-PAGE (10-12% gels are typically suitable)

• Transfer proteins to nitrocellulose or PVDF membrane

• Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary antibody at dilutions between 1:500-1:2000 in blocking buffer overnight at 4°C

• Wash membrane 3-5 times with TBST

• Incubate with HRP-conjugated secondary antibody

• Visualize using chemiluminescence detection system

• Include a blocking peptide control by pre-incubating the antibody with synthesized peptide to confirm specificity

The cleaved NOTCH2 typically appears as a band of approximately 110 kDa .

How can researchers validate the specificity of this antibody in experimental settings?

Researchers should implement multiple validation strategies:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to block specific binding. This should eliminate true positive signals while nonspecific binding remains .

• Positive controls: Use cell lines with known NOTCH2 activation, such as Jurkat cells treated with etoposide, which induces NOTCH2 cleavage .

• Genetic validation: Compare staining in wild-type versus NOTCH2-knockout or NOTCH2-mutated samples.

• Comparison with alternative detection methods: Validate findings with other approaches that detect NOTCH2 activation, such as qPCR for NOTCH2 target genes or alternative antibodies targeting different epitopes of activated NOTCH2.

• Pharmacological inhibition: Treat samples with γ-secretase inhibitors to prevent NOTCH2 cleavage, which should reduce or eliminate signal from this antibody .

What considerations should be made for immunohistochemistry applications with this antibody?

For immunohistochemistry applications:

• Sample preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues should be cut onto charged slides at 4-μm thickness

  • Bake slides at 60°C for 1 hour

  • Perform epitope retrieval (based on protocols similar to those used in NOTCH2 studies)

• Staining protocol:

  • Use automated immunostainer if available

  • Recommended dilution range: Start with 1:50-1:100

  • Incubation time: 60 minutes at room temperature

  • Develop staining with secondary antibody linked to horseradish peroxidase followed by diaminobenzidine

  • Counterstain with hematoxylin

• Controls:

  • Include positive tissue controls (such as reactive lymphoid tissues)

  • Include negative controls by omitting primary antibody

  • Compare with total NOTCH2 staining patterns

How can this antibody be used to study NOTCH2 activation in disease models?

This antibody has proven valuable for studying NOTCH2 activation in various disease models:

• B-cell lymphomas:

  • The antibody has been used to demonstrate that NOTCH2 activation is pervasive in splenic marginal zone lymphoma (SMZL) but uncommon in diffuse large B-cell lymphoma (DLBCL)

  • Studies show distinct nuclear staining patterns in NOTCH2-mutated SMZL compared to normal tissues

• Bone disorders:

  • Research using anti-NOTCH2 antibodies has shown reversal of osteopenic phenotypes in mouse models of Hajdu-Cheney syndrome, where NOTCH2 mutations result in enhanced NOTCH2 signaling

• Developmental studies:

  • The antibody can be used to track NOTCH2 activation in developmental fate decisions, as demonstrated in studies of B cell differentiation between germinal center and plasma cell lineages

• Cancer research:

  • Can be applied to identify NOTCH2 activation in cancer samples, particularly in contexts where NOTCH signaling affects chemotherapy response

When designing studies, researchers should consider tissue-specific expression patterns and the dynamic nature of NOTCH2 signaling across different physiological contexts.

What are important considerations for using this antibody in multiplexed immunostaining protocols?

When incorporating Cleaved-NOTCH2 (V1697) Antibody into multiplexed staining:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different host species to avoid cross-reactivity

  • Consider using antibodies against related markers such as BCL6 for comprehensive pathway analysis

• Sequential staining consideration:

  • Determine optimal order of antibody application

  • Consider tyramide signal amplification for sequential multiplexing

• Signal separation:

  • Use spectrally distinct fluorophores for multi-color imaging

  • Implement appropriate controls to confirm signal specificity for each antibody

• Image analysis:

  • Use appropriate software to separate signals and quantify co-localization

  • Consider cell-by-cell analysis for heterogeneous tissues

• Contextual markers:

  • Include markers for cellular compartments to properly interpret NOTCH2 activation

  • Nuclear counterstains are essential for confirming nuclear localization of cleaved NOTCH2

How does this antibody compare with other methods for detecting NOTCH2 activation?

Research has demonstrated that antibodies recognizing the NICD2 neoepitope provide more accurate assessment of NOTCH2 activation than total NOTCH2 antibodies, particularly in diseases with NOTCH2 mutations .

What staining patterns indicate active NOTCH2 signaling, and how should researchers interpret variability in signal intensity?

Characteristic staining patterns of active NOTCH2 signaling include:

• Nuclear localization: Active cleaved NOTCH2 translocates to the nucleus to regulate gene expression. Strong nuclear staining is the primary indicator of NOTCH2 activation .

• Intensity variation: Studies in splenic tissue have shown that NOTCH2-mutated samples display "much more intense and pervasive nuclear NICD2 staining" compared to normal tissues with only "weak to moderate nuclear NICD2 staining in a subset of cells" .

• Tissue-specific patterns:

  • In normal tissues: Weak to moderate nuclear staining in splenic marginal zone B cells

  • In pathological samples: Intense nuclear staining in cells with NOTCH2 mutations or activation

• Temporal dynamics: NOTCH2 activation can be transient during developmental processes, showing initial activation followed by downregulation, as observed in B cell differentiation studies .

When interpreting variability in signal intensity, researchers should consider:

• Heterogeneity within cell populations

• Influence of microenvironmental factors on NOTCH2 activation

• Technical variables including fixation time, antibody concentration, and detection methods

Potential causes of false positives:

• Cross-reactivity: The antibody may detect other cleaved NOTCH family members (particularly NOTCH1) if not properly validated.

• Non-specific binding: High antibody concentrations can lead to non-specific binding to other proteins, particularly in certain fixation conditions.

• Endogenous peroxidase activity: Insufficient blocking of endogenous peroxidases in tissues can cause background in IHC applications.

• Edge effects: Tissue edges may show artifactual staining due to physical damage during processing.

Potential causes of false negatives:

• Epitope masking: Improper fixation or inadequate antigen retrieval can mask the epitope.

• Insufficient cleavage: Samples with low γ-secretase activity may have reduced NOTCH2 cleavage despite pathway activation.

• Rapid degradation: Cleaved NOTCH2 has a short half-life that can be extended by mutations in the FBXW7 gene (which normally mediates NIC degradation) .

• Technical issues: Suboptimal antibody concentration, incubation time, or detection systems can result in weak or absent signal despite presence of the target.

How should researchers resolve contradictory results between this antibody and other NOTCH2 detection methods?

When faced with contradictory results:

• Verify antibody specificity: Implement peptide competition assays to confirm that observed signals are specific to cleaved NOTCH2 .

• Evaluate detection limitations: Consider that different methods detect different aspects of NOTCH2 biology:

  • Cleaved-NOTCH2 antibody detects only the activated form

  • Total NOTCH2 antibodies detect both active and inactive forms

  • Functional assays measure downstream effects

• Implement orthogonal validation:

  • Confirm NOTCH2 activation through target gene expression (HES1, IRF4)

  • Use genetic models with constitutive NOTCH2IC expression or NOTCH2 knockout as reference points

  • Consider pharmacological manipulation with γ-secretase inhibitors

• Evaluate temporal dynamics: NOTCH2 signaling is often dynamic and context-dependent. Discrepancies might reflect different temporal phases of activation.

• Consider biological complexity:

  • Post-translational modifications might affect epitope accessibility

  • NOTCH2 mutations can alter protein stability and detection

  • Regulatory feedback mechanisms may cause complex patterns of activation

The research by Valls and colleagues demonstrates that "Notch2 surface expression and signaling are induced in activated follicular B cells" but must be "switched off to enable their terminal differentiation," highlighting the dynamic nature of NOTCH2 signaling that may explain seemingly contradictory results .

How can this antibody be used to study the interplay between NOTCH2 signaling and other pathways?

The Cleaved-NOTCH2 (V1697) Antibody can be instrumental in studying pathway crosstalk:

• NOTCH2 and cell fate decisions:

  • Research has shown that "Notch2 signaling regulates a fate choice in antigen activated Follicular B cells" between germinal center and plasma cell differentiation

  • The antibody can be used alongside markers of other pathways (e.g., IRF4, Blimp1) to track these decisions

• NOTCH2 in therapeutic contexts:

  • Studies using antibodies against the negative regulatory region (NRR) of NOTCH2 demonstrate potential therapeutic applications by "locking the receptor in its quiescent state"

  • Researchers can use the V1697 antibody to monitor efficacy of such interventions

• Role in cancer and chemoresistance:

  • NOTCH2 signaling has been implicated in regulating "cell proliferation, apoptosis, stem cell self-renewal, and differentiation in a context-dependent fashion"

  • This antibody can help determine if NOTCH2 activation correlates with resistance to specific chemotherapeutic agents

• Developmental biology applications:

  • NOTCH2 has distinct roles from other NOTCH family members in development

  • For instance, "Notch2 regulates the quiescence of ventricular-subventricular zone NSCs, and its effectors block cell-cycle entry"

  • This antibody can help distinguish NOTCH2-specific effects from those of other NOTCH proteins

What considerations should be made when using this antibody to study NOTCH2 mutations in disease models?

When studying NOTCH2 mutations:

• Mutation-specific effects:

  • Different mutations may affect antibody binding or NOTCH2 processing

  • For example, in Hajdu-Cheney syndrome, a point mutation (C>T) leads to a Q2319X change that enhances NOTCH2 signaling

  • Researchers should verify antibody recognition in their specific mutant models

• Alternative cleavage sites:

  • Some mutations may create alternative cleavage sites or alter processing

  • This antibody specifically recognizes cleavage at V1697, so alternative processing may go undetected

• Changes in localization:

  • Mutations may affect nuclear translocation or retention

  • As noted in one study, "Following proteolytical processing NICD is translocated to the nucleus. Retained at the cytoplasm by TCIM"

  • Comprehensive spatial analysis should accompany activation studies

• Altered stability:

  • Mutations in regulatory domains can extend protein half-life

  • For instance, "loss-of-function mutations in the FBXW7 gene, by preventing the FBXW7-mediated NIC degradation, extend its half-life and amplify the output of the signal"

  • Time-course studies may be necessary to capture these dynamics